Edelman Steven, Pettus Jeremy
Department of Endocrinology and Metabolism, VA San Diego Healthcare Center, San Diego, Calif.
Department of Endocrinology, University of California, San Diego, Calif.
Am J Med. 2014 Oct;127(10 Suppl):S11-6. doi: 10.1016/j.amjmed.2014.07.003.
Despite advances in treatment for type 2 diabetes in recent decades, many patients are failing to achieve adequate glycemic control. Poor glycemic control has been shown to have a detrimental effect on patients' health and well-being, and to have significant negative financial implications for both patients and healthcare systems. Insulin therapy has been proven to significantly reduce glycated hemoglobin levels; however, both patients and physicians can be reluctant to initiate insulin therapy. Research shows that both patient and provider factors contribute to a delay in initiation of insulin therapy. This review discusses the most common barriers contributing to this delay with potential solutions to overcome them.
尽管近几十年来2型糖尿病的治疗取得了进展,但许多患者仍未能实现充分的血糖控制。血糖控制不佳已被证明会对患者的健康和幸福产生不利影响,并给患者和医疗系统带来重大的负面经济影响。胰岛素治疗已被证明能显著降低糖化血红蛋白水平;然而,患者和医生都可能不愿意开始胰岛素治疗。研究表明,患者和医疗服务提供者的因素都会导致胰岛素治疗开始延迟。这篇综述讨论了导致这种延迟的最常见障碍以及克服这些障碍的潜在解决方案。